Novel Fused Pyrimidines as Potent Cyclin‐Dependent Kinases Inhibitor for Gastric Adenocarcinoma: Combined In Vitro, In Silico Anticancer Studies.

MLA

Saravanakumar, Natarajan, et al. “Novel Fused Pyrimidines as Potent Cyclin‐Dependent Kinases Inhibitor for Gastric Adenocarcinoma: Combined In Vitro, In Silico Anticancer Studies.” Chemical Biology & Drug Design, vol. 104, no. 5, Nov. 2024, pp. 1–16. EBSCOhost, https://doi.org/10.1111/cbdd.70013.

APA

Saravanakumar, N., Poorani, A. S. A., Dhanabalan, A. K., Sugapriya, S., Kumaresan, G., & Suresh, P. (2024). Novel Fused Pyrimidines as Potent Cyclin‐Dependent Kinases Inhibitor for Gastric Adenocarcinoma: Combined In Vitro, In Silico Anticancer Studies. Chemical Biology & Drug Design, 104(5), 1–16. https://doi.org/10.1111/cbdd.70013

Chicago

Saravanakumar, Natarajan, Arunagiri Sivanesan Aruna Poorani, Anantha Krishnan Dhanabalan, Selvam Sugapriya, Ganesan Kumaresan, and Palaniswamy Suresh. 2024. “Novel Fused Pyrimidines as Potent Cyclin‐Dependent Kinases Inhibitor for Gastric Adenocarcinoma: Combined In Vitro, In Silico Anticancer Studies.” Chemical Biology & Drug Design 104 (5): 1–16. doi:10.1111/cbdd.70013.